title: Novel oral anticoagulants: what dermatologists need to know.
abstract: The development of novel oral anticoagulants provides clinicians and patients a welcome alternative to the challenges of warfarin therapy. Dermatologists must be aware of the potential impact of novel oral anticoagulants on their surgical and medical practice. This review provides a concise summary of the novel oral anticoagulants for dermatologists with particular emphasis on: (1) the pharmacokinetic properties of these drugs and how they differ from warfarin, (2) suggested management during cutaneous surgery, (3) adverse drug interactions with commonly prescribed medications in dermatology, and (4) potential use within dermatology for treatment of disorders of cutaneous thrombosis.
authors.affiliation: Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
authors.forename: Molly
authors.initials: M
authors.lastname: Plovanich
authors.affiliation: Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: amostaghimi@partners.org.
authors.forename: Arash
authors.initials: A
authors.lastname: Mostaghimi
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D062109:Dermatologic Surgical Procedures; D003880:Dermatology; D004347:Drug Interactions; D006801:Humans
chemical_list: D000925:Anticoagulants
keywords: anticoagulation; apixaban; cutaneous surgery; dabigatran; novel drugs; rivaroxaban; warfarin